12:00 AM
 | 
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CellSearch Circulating Tumor Cell Kit: Clinical trial data

A double-blind, Chinese trial analyzing blood samples from 294 evaluable patients with metastatic breast cancer showed that detection of <5 CTCs at baseline as measured by Veridex LLC's CellSearch Circulating Tumor Cell Kit predicted significantly longer median PFS (9 vs. 6.7 months, p<0.001) and OS (>24.6 vs. 13.2 months, p<0.001)...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >